ArticleOncoimmunology2012
Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLs.
Article in Oncoimmunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Trial watch: TLR3 agonists in cancer therapy.Oncoimmunology · 2020Review
- IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma.Cancer management and research · 2019Article
- Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination.Mediators of inflammation · 2016Review
- Dendritic cell vaccines containing lymphocytes produce improved immunogenicity in patients with cancer.Journal of translational medicine · 2014Article
- Therapeutic cancer vaccines and combination immunotherapies involving vaccination.ImmunoTargets and therapy · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Activated lymphocytes secrete dendritic cell (DC)-activating cytokines including tumor necrosis factor α and interferon γ, and induce Type-1-polarized DCs (DC1s). Lymphocyte-polarized DC1s secrete high levels of biologically active interleukin-12 (IL-12p70) and CXCL10 and show enhanced CTL-inducing activity. Our data demonstrate the feasibility of using autologous lymphocytes to enhance the immunogenic properties of DCs in a low-cost clinically-compatible process.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.